The incidence of thyroid cancer has been steadily increasing. Differentiated, medullary, and anaplastic are the three main types of thyroid cancer. Vandetanib, an oral tyrosine kinase inhibitor, has shown efficacy against medullary thyroid cancer. It is available in 300- and 100-mg tablets, with a recommended daily dose of 300 mg once daily. Vandetanib has a role in therapy for patients with unresectable, locally advanced or metastatic medullary thyroid cancer and has shown improved progression-free survival compared to placebo. It requires routine monitoring of ECGs and electrolytes due to potential adverse effects.
1. Thyroid cancer incidence is increasing steadily. 2. Vandetanib, an oral tyrosine kinase inhibitor, is used to treat medullary thyroid cancer. 3. Recommended daily dose of oral vandetanib is 300 mg. 4. Vandetanib requires routine monitoring of ECGs and electrolytes. 5. It has shown improved progression-free survival compared to placebo.
Listen Tab content
